P/B
5,9
RenovoRx
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
$54.5M
Market Cap • 11/6/2026
2012
(14 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
19,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,2
EPS
—
Market Cap
Market Cap
54,5M
EV
44,3M
EV/Revenue
16
EV/EBITDA
-3,3
EV/EBIT
-3,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-46,9%
Total Yield
-46,9%
Payout
0%
Retained Earnings
-71,5M
Profitability
Gross Margin
84%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
186,2%
Capex/Revenue
3,2%
Capex/D&A
750%
Capex/OCF
-0,7%
SBC/OCF
—
% PPE
3,4%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
28%
CAGR Net Income 5Y
22,3%
CAGR EPS 5Y
-29,3%
CAGR OCF 5Y
22,9%
Leverage
N.D./EBITDA
0,8
Debt/Equity
0%
Current Ratio
5,6
Quick Ratio
5,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!